Lipid Nanoparticle Preparations for Diverse Drug Administrations

Suruihao Liu

doi:10.54097/qd03cp44

Authors

Suruihao Liu

DOI:

https://doi.org/10.54097/qd03cp44

Keywords:

LNP, Drug Delivery, Gene Therapy, Injectable Administrations, LNP Preparation

Abstract

The lipid nanoparticle (LNP) system serves as a crucial non-viral vector, playing a pivotal role in the realm of gene therapy delivery. Beyond its primary purpose, LNP modifications broaden its utility, spanning diverse application realms and administration methods. An array of LNP preparation technologies has emerged, tailored to meet varied requirements and categorized based on the specific mode of drug administration. This review systematically classifies common modes of administration suitable for LNPs, providing a comprehensive overview. Subsequently, it delves into specific examples of LNP preparation techniques designed for different administration routes, elucidating the achieved outcomes. The article meticulously analyzes the similarities and distinctions in LNP preparation methodologies across various routes of administration, with a keen focus on the unique demands posed by each route in terms of LNP composition and structure.

Downloads

Download data is not yet available.

References

[1] Kenjo, E., et al., Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice. Nat Commun, 2021. 12(1): p. 7101.

[2] Kiaie, S.H., et al., Recent advances in mRNA-LNP therapeutics: immunological and pharmacological aspects. J Nanobiotechnology, 2022. 20(1): p. 276.

[3] Eygeris, Y., et al., Chemistry of Lipid Nanoparticles for RNA Delivery. Accounts of Chemical Research, 2022. 55(1): p. 2-12.

[4] Ndeupen, S., et al., The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory. iScience, 2021. 24(12): p. 103479.

[5] Vlatkovic, I., Non-Immunotherapy Application of LNP-mRNA: Maximizing Efficacy and Safety. Biomedicines, 2021. 9(5).

[6] Müller, R.H., K. Mäder, and S. Gohla, Solid lipid nanoparticles (SLN) for controlled drug delivery–a review of the state of the art. European journal of pharmaceutics and biopharmaceutics, 2000. 50(1): p. 161-177.

[7] Carrasco, M.J., et al., Ionization and structural properties of mRNA lipid nanoparticles influence expression in intramuscular and intravascular administration. Commun Biol, 2021. 4(1): p. 956.

[8] Wong, J., et al., Suspensions for intravenous (IV) injection: A review of development, preclinical and clinical aspects. Advanced Drug Delivery Reviews, 2008. 60(8): p. 939-954.

[9] Wacker, M., Nanocarriers for intravenous injection—The long hard road to the market. International Journal of Pharmaceutics, 2013. 457(1): p. 50-62.

[10] Davies, N., et al., Functionalized lipid nanoparticles for subcutaneous administration of mRNA to achieve systemic exposures of a therapeutic protein. Molecular Therapy-Nucleic Acids, 2021. 24: p. 369-384.

[11] Mishra, D., et al., Evaluation of solid lipid nanoparticles as carriers for delivery of hepatitis B surface antigen for vaccination using subcutaneous route. Journal of pharmacy & pharmaceutical sciences, 2010. 13(4): p. 495-509.

[12] Hassett, K.J., et al., Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines. Molecular Therapy-Nucleic Acids, 2019. 15: p. 1-11.

[13] Hou, X., et al., Lipid nanoparticles for mRNA delivery. Nature Reviews Materials, 2021. 6(12): p. 1078-1094.

[14] Melamed, J.R., et al., Ionizable lipid nanoparticles deliver mRNA to pancreatic β cells via macrophage-mediated gene transfer. Science Advances, 2023. 9(4): p. eade1444.

[15] Kenjo, E., et al., Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice. Nature communications, 2021. 12(1): p. 7101.

[16] Novobrantseva, T.I., et al., Systemic RNAi-mediated gene silencing in nonhuman primate and rodent myeloid cells. Molecular Therapy-Nucleic Acids, 2012. 1.

[17] de Souza Guedes, L., et al., An overview on topical administration of carotenoids and coenzyme Q10 loaded in lipid nanoparticles. Antioxidants, 2021. 10(7): p. 1034.

[18] Puglia, C., et al., Design of solid lipid nanoparticles for caffeine topical administration. Drug Delivery, 2016. 23(1): p. 36-40.

[19] Mahajan, M., et al., Solid lipid nanoparticles as carrier to increase local bioavailability of acitretin after topical administration in psoriasis treatment. Journal of Pharmaceutical Innovation, 2023. 18(1): p. 220-237.

[20] Cavalli, R., et al., Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. International journal of pharmaceutics, 2002. 238(1-2): p. 241-245.

[21] Leong, E.W. and R. Ge, Lipid nanoparticles as delivery vehicles for inhaled therapeutics. Biomedicines, 2022. 10(9): p. 2179.

[22] Kim, J., et al., Engineering lipid nanoparticles for enhanced intracellular delivery of mRNA through Inhalation. ACS nano, 2022. 16(9): p. 14792-14806.

[23] Yoon, G., J.W. Park, and I.-S. Yoon, Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs): recent advances in drug delivery. Journal of Pharmaceutical Investigation, 2013. 43: p. 353-362.

[24] Weber, S., A. Zimmer, and J. Pardeike, Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for pulmonary application: a review of the state of the art. European Journal of Pharmaceutics and Biopharmaceutics, 2014. 86(1): p. 7-22.

[25] Hitzman, C.J., et al., Development of a respirable, sustained release microcarrier for 5-fluorouracil I: In vitro assessment of liposomes, microspheres, and lipid coated nanoparticles. Journal of pharmaceutical sciences, 2006. 95(5): p. 1114-1126.

[26] Aditya, N., et al., Arthemeter-loaded lipid nanoparticles produced by modified thin-film hydration: Pharmacokinetics, toxicological and in vivo anti-malarial activity. European Journal of Pharmaceutical Sciences, 2010. 40(5): p. 448-455.

[27] Evers, M.J., et al., State‐of‐the‐art design and rapid‐mixing production techniques of lipid nanoparticles for nucleic acid delivery. Small Methods, 2018. 2(9): p. 1700375.

[28] Leung, A.K., et al., Microfluidic mixing: a general method for encapsulating macromolecules in lipid nanoparticle systems. The Journal of Physical Chemistry B, 2015. 119(28): p. 8698-8706.

[29] Belliveau, N.M., et al., Microfluidic synthesis of highly potent limit-size lipid nanoparticles for in vivo delivery of siRNA. Molecular Therapy-Nucleic Acids, 2012. 1.

[30] Zhigaltsev, I.V., et al., Bottom-up design and synthesis of limit size lipid nanoparticle systems with aqueous and triglyceride cores using millisecond microfluidic mixing. Langmuir, 2012. 28(7): p. 3633-3640.

[31] Schubert, M. and C. Müller-Goymann, Solvent injection as a new approach for manufacturing lipid nanoparticles–evaluation of the method and process parameters. European journal of pharmaceutics and biopharmaceutics, 2003. 55(1): p. 125-131.

[32] Battaglia, L. and M. Gallarate, Lipid nanoparticles: state of the art, new preparation methods and challenges in drug delivery. Expert opinion on drug delivery, 2012. 9(5): p. 497-508.

[33] Zhu, J., et al., Towards sustainable production and utilization of plant-biomass-based nanomaterials: a review and analysis of recent developments. Biotechnology for Biofuels, 2021. 14(1): p. 114.

[34] Kulkarni, J.A., P.R. Cullis, and R. Van Der Meel, Lipid nanoparticles enabling gene therapies: from concepts to clinical utility. Nucleic acid therapeutics, 2018. 28(3): p. 146-157.

[35] Perona, J.S. and V. Ruiz-Gutierrez, Simultaneous determination of molecular species of monoacylglycerols, diacylglycerols and triacylglycerols in human very-low-density lipoproteins by reversed-phase liquid chromatography. Journal of Chromatography B, 2003. 785(1): p. 89-99.

[36] Mousli, Y., et al., A rapid and quantitative reversed-phase HPLC-DAD/ELSD method for lipids involved in nanoparticle formulations. Journal of Pharmaceutical and Biomedical Analysis, 2022. 220: p. 115011.

[37] Arıca Yegin, B., J.-P. Benoît, and A. Lamprecht, Paclitaxel-loaded lipid nanoparticles prepared by solvent injection or ultrasound emulsification. Drug development and industrial pharmacy, 2006. 32(9): p. 1089-1094.

[38] Khairnar, S.V., et al., Review on the scale-up methods for the preparation of solid lipid nanoparticles. Pharmaceutics, 2022. 14(9): p. 1886.

[39] Liu, Y., Y. Zhao, and X. Feng, Exergy analysis for a freeze-drying process. Applied Thermal Engineering, 2008. 28(7): p. 675-690.

[40] Mancini, G., et al., Lecithin and parabens play a crucial role in tripalmitin‐based lipid nanoparticle stabilization throughout moist heat sterilization and freeze‐drying. European Journal of Lipid Science and Technology, 2015. 117(12): p. 1947-1959.

[41] Kedmi, R., N. Ben-Arie, and D. Peer, The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation. Biomaterials, 2010. 31(26): p. 6867-6875.

[42] Ishida, T., et al., Accelerated clearance of a second injection of PEGylated liposomes in mice. International journal of pharmaceutics, 2003. 255(1-2): p. 167-174.

[43] Baek, J.S., et al., Modification of paclitaxel-loaded solid lipid nanoparticles with 2-hydroxypropyl-β-cyclodextrin enhances absorption and reduces nephrotoxicity associated with intravenous injection. Int J Nanomedicine, 2015. 10: p. 5397-405.

[44] Szebeni, J., et al., Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention. Advanced drug delivery reviews, 2011. 63(12): p. 1020-1030.

[45] Nogueira, S.S., et al., Polysarcosine-Functionalized Lipid Nanoparticles for Therapeutic mRNA Delivery. ACS Applied Nano Materials, 2020. 3(11): p. 10634-10645.

[46] Carrasco, M.J., et al., Ionization and structural properties of mRNA lipid nanoparticles influence expression in intramuscular and intravascular administration. Communications biology, 2021. 4(1): p. 956.

[47] Chen, S., et al., Development of lipid nanoparticle formulations of siRNA for hepatocyte gene silencing following subcutaneous administration. Journal of Controlled Release, 2014. 196: p. 106-112.

[48] Zhao, Y., et al., A frustrating problem: accelerated blood clearance of PEGylated solid lipid nanoparticles following subcutaneous injection in rats. European Journal of Pharmaceutics and Biopharmaceutics, 2012. 81(3): p. 506-513.

[49] Davies, N., et al., Functionalized lipid nanoparticles for subcutaneous administration of mRNA to achieve systemic exposures of a therapeutic protein. Mol Ther Nucleic Acids, 2021. 24: p. 369-384.

[50] Anthiya, S., et al., Targeted siRNA lipid nanoparticles for the treatment of KRAS-mutant tumors. Journal of Controlled Release, 2023. 357: p. 67-83.

[51] Chen, S., et al., Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA. Journal of Controlled Release, 2016. 235: p. 236-244.

[52] Xie, S., et al., Preparation, characterization and pharmacokinetics of enrofloxacin-loaded solid lipid nanoparticles: Influences of fatty acids. Colloids and Surfaces B: Biointerfaces, 2011. 83(2): p. 382-387.

[53] Din, F.u., et al., Irinotecan-loaded double-reversible thermogel with improved antitumor efficacy without initial burst effect and toxicity for intramuscular administration. Acta Biomaterialia, 2017. 54: p. 239-248.

[54] Zukancic, D., et al., The Importance of Poly(ethylene glycol) and Lipid Structure in Targeted Gene Delivery to Lymph Nodes by Lipid Nanoparticles. Pharmaceutics, 2020. 12(11): p. 1068.

[55] Ni, H., et al., Piperazine-derived lipid nanoparticles deliver mRNA to immune cells in vivo. Nat Commun, 2022. 13(1): p. 4766.

[56] Tilstra, G., et al., Iterative Design of Ionizable Lipids for Intramuscular mRNA Delivery. Journal of the American Chemical Society, 2023. 145(4): p. 2294-2304.

[57] Priano, L., et al., Baclofen-loaded solid lipid nanoparticles: preparation, electrophysiological assessment of efficacy, pharmacokinetic and tissue distribution in rats after intraperitoneal administration. European Journal of Pharmaceutics and Biopharmaceutics, 2011. 79(1): p. 135-141.

[58] Dal Magro, R., et al., ApoE-modified solid lipid nanoparticles: A feasible strategy to cross the blood-brain barrier. Journal of Controlled Release, 2017. 249: p. 103-110.

[59] Rosenblum, D., et al., CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy. Science advances, 2020. 6(47): p. eabc9450.

[60] Figueiredo, P., et al., Peptide-guided resiquimod-loaded lignin nanoparticles convert tumor-associated macrophages from M2 to M1 phenotype for enhanced chemotherapy. Acta biomaterialia, 2021. 133: p. 231-243.

[61] Alvarez-Trabado, J., Y. Diebold, and A. Sanchez, Designing lipid nanoparticles for topical ocular drug delivery. International Journal of Pharmaceutics, 2017. 532(1): p. 204-217.

[62] Chen, Y.-C., et al., Development of terbinafine solid lipid nanoparticles as a topical delivery system. International Journal of Nanomedicine, 2012: p. 4409-4418.

[63] Ferreira, M., et al., Topical co-delivery of methotrexate and etanercept using lipid nanoparticles: A targeted approach for psoriasis management. Colloids and Surfaces B: Biointerfaces, 2017. 159: p. 23-29.

[64] de Souza Guedes, L., et al., An Overview on Topical Administration of Carotenoids and Coenzyme Q10 Loaded in Lipid Nanoparticles. Antioxidants (Basel), 2021. 10(7).

[65] Jones, K.L., D. Drane, and E.J. Gowans, Long-term storage of DNA-free RNA for use in vaccine studies. Biotechniques, 2007. 43(5): p. 675-681.

[66] Wollner, C.J., et al., A dengue virus serotype 1 mRNA-LNP vaccine elicits protective immune responses. Journal of Virology, 2021. 95(12): p. 10.1128/jvi. 02482-20.

[67] Tam, A., et al., Lipid nanoparticle formulations for optimal RNA-based topical delivery to murine airways. European Journal of Pharmaceutical Sciences, 2022. 176: p. 106234.

[68] Li, Y.-Z., et al., Inhalable microparticles as carriers for pulmonary delivery of thymopentin-loaded solid lipid nanoparticles. Pharmaceutical research, 2010. 27: p. 1977-1986.

[69] Naseri, N., H. Valizadeh, and P. Zakeri-Milani, Solid Lipid Nanoparticles and Nanostructured Lipid Carriers: Structure, Preparation and Application. Adv Pharm Bull, 2015. 5(3): p. 305-13.

[70] Gaspar, D.P., et al., Rifabutin-loaded solid lipid nanoparticles for inhaled antitubercular therapy: Physicochemical and in vitro studies. International Journal of Pharmaceutics, 2016. 497(1): p. 199-209.

[71] Gaspar, D.P., et al., Rifabutin-loaded solid lipid nanoparticles for inhaled antitubercular therapy: Physicochemical and in vitro studies. International journal of pharmaceutics, 2016. 497(1-2): p. 199-209.

[72] van Lummel, M., et al., Enriching lipid nanovesicles with short-chain glucosylceramide improves doxorubicin delivery and efficacy in solid tumors. The FASEB Journal, 2011. 25(1): p. 280-289.

[73] Scheideler, M., I. Vidakovic, and R. Prassl, Lipid nanocarriers for microRNA delivery. Chemistry and Physics of Lipids, 2020. 226: p. 104837.

[74] Nabhan, J.F., et al., Intrathecal delivery of frataxin mRNA encapsulated in lipid nanoparticles to dorsal root ganglia as a potential therapeutic for Friedreich’s ataxia. Scientific Reports, 2016. 6(1): p. 20019.

[75] Maugeri, M., et al., Linkage between endosomal escape of LNP-mRNA and loading into EVs for transport to other cells. Nature Communications, 2019. 10(1): p. 4333.

[76] Maeki, M., et al., Advances in microfluidics for lipid nanoparticles and extracellular vesicles and applications in drug delivery systems. Advanced Drug Delivery Reviews, 2018. 128: p. 84-100.

[77] Kawaguchi, M., et al., Effect of Cholesterol Content of Lipid Composition in mRNA-LNPs on the Protein Expression in the Injected Site and Liver After Local Administration in Mice. Journal of Pharmaceutical Sciences, 2023. 112(5): p. 1401-1410.

[78] Kulkarni, J.A., et al., On the Formation and Morphology of Lipid Nanoparticles Containing Ionizable Cationic Lipids and siRNA. ACS Nano, 2018. 12(5): p. 4787-4795.

[79] Lindgren, G., et al., Induction of Robust B Cell Responses after Influenza mRNA Vaccination Is Accompanied by Circulating Hemagglutinin-Specific ICOS+ PD-1+ CXCR3+ T Follicular Helper Cells. Frontiers in Immunology, 2017. 8.

[80] Guimaraes, P.P.G., et al., Ionizable lipid nanoparticles encapsulating barcoded mRNA for accelerated in vivo delivery screening. Journal of Controlled Release, 2019. 316: p. 404-417.

[81] Maeta, M., et al., Vitamin E Scaffolds of pH-Responsive Lipid Nanoparticles as DNA Vaccines in Cancer and Protozoan Infection. Molecular Pharmaceutics, 2020. 17(4): p. 1237-1247.

[82] González-Aramundiz, J.V., et al., Rational design of protamine nanocapsules as antigen delivery carriers. Journal of Controlled Release, 2017. 245: p. 62-69.

[83] Bruschi, M., et al., Association between maternal omega-3 polyunsaturated fatty acids supplementation and preterm delivery: A proteomic study. The FASEB Journal, 2020. 34(5): p. 6322-6334.

[84] Kulkarni, J.A., et al., Design of lipid nanoparticles for in vitro and in vivo delivery of plasmid DNA. Nanomedicine: Nanotechnology, Biology and Medicine, 2017. 13(4): p. 1377-1387.

[85] Kolenyak-Santos, F., et al., Nanostructured Lipid Carriers as a Strategy to Improve the In Vitro Schistosomiasis Activity of Praziquantel. Journal of nanoscience and nanotechnology, 2015. 15(1): p. 761-772.